Detalhe da pesquisa
1.
Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
J Pharmacol Exp Ther
; 384(1): 173-186, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36310034
2.
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
Xenobiotica
; 52(6): 555-566, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052821
3.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
; 391(10121): 659-667, 2018 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241979
4.
Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
Drug Metab Dispos
; 47(2): 145-154, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442651
5.
An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners.
Br J Clin Pharmacol
; 81(2): 362-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26447647
6.
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.
Genome Res
; 20(8): 1020-36, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20538623
7.
Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
Drug Metab Dispos
; 41(9): 1598-609, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23792813
8.
Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.
Xenobiotica
; 43(7): 617-27, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23244593
9.
Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers.
Drug Metab Dispos
; 40(5): 928-42, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22328582
10.
Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(5): 640-653, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172043
11.
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
J Clin Pharmacol
; 62(6): 812-822, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34897701
12.
Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.
Drug Metab Dispos
; 39(8): 1415-22, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21555507
13.
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
CPT Pharmacometrics Syst Pharmacol
; 8(7): 489-499, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044521
14.
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Clin Pharmacokinet
; 58(5): 659-672, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30556110
15.
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
Eur J Pharm Biopharm
; 142: 435-448, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306750
16.
In vitro metabolic activation of lumiracoxib in rat and human liver preparations.
Drug Metab Dispos
; 36(2): 469-73, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17998295
17.
Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis.
Clin Pharmacokinet
; 56(2): 179-192, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27517676
18.
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.
J Clin Pharmacol
; 57(4): 513-523, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27667740
19.
The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E.
J Clin Pharmacol
; 43(10): 1161-7, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14517199
20.
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.
AAPS J
; 15(4): 933-40, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23794076